Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
HEДокторантска мрежа2023–2027

IgG4-TREAT · Systematic study of IgG4-autoimmune diseases to develop new treatment strategies

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2023-09-01 → 2027-08-31
Финансиране от ЕС
2 626 812 €
Участници
20
Схема
HORIZON-TMA-MSCA-DN

Линиите свързват координатора с партньорите.

Накратко на български

Автоимунните заболявания, причинени от антитела от тип IgG4, засягат органи като мозъка, нервите и мускулите. Разбирането на механизмите им помага за създаване на по-точни терапии, които да премахват само вредните антитела, без да засягат полезните.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Systematic study of IgG4-autoimmune diseases to develop new treatment strategies

Autoimmune diseases are the result when the immune system targets its own organs and tissues. We recently described a specific group of autoimmune diseases, termed "IgG4-mediated autoimmune diseases" (IgG4-AID), which are caused by a specific antibody type, IgG4. These diseases can affect different organs, including the brain, nerves, and muscles, and while each is rare, together they impact an estimated half a million people across the European Union. Patients often experience delayed diagnosis, limited treatment options, and relapses despite therapy, leading to long-term health problems and reduced quality of life. The IgG4 subclass has unique biological properties that distinguish it from other antibodies. Instead of activating the immune system, IgG4 interferes with cellular communication and tissue integrity, representing a new paradigm in autoimmunity. It is unclear why the immune system produces harmful IgG4 antibodies, and current treatments rely on non-specific immunosuppression or plasma exchange, which are not equally effective for all patients and may cause serious side effects. The IgG4-TREAT addressees knowledge gaps by combining scientific excellence and interdisciplinary training within a EU research network. Experts in neuroimmunology, molecular biology, and clinical sciences collaborate to uncover the cellular, molecular, and genetic mechanisms driving pathogenic IgG4 antibodies. By analysing patient samples and advanced molecular profiling, the consortium aims to identify disease drivers and biomarkers that can guide the development of new, targeted therapies. Further, IgG4-TREAT aims to develop a new disease model and an innovative therapeutic approach capable of selectively removing harmful IgG4 antibodies without affecting beneficial ones. Beyond its scientific objectives, IgG4-TREAT is dedicated to train the next generation of scientists by offering an innovative training programme. The project fosters responsible and inclusive research practices, including sustainable laboratory work, gender equality, resilience in academia, and open science. By integrating advanced research with high-quality training, IgG4-TREAT contributes to improved understanding and treatment of rare autoimmune diseases, enhances diagnostic precision, and strengthens EU leadership in biomedical innovation. The long-term impact is expected to include better patient outcomes, improved healthcare, and new opportunities for biomedical innovation across Europe.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

IgG4-autoimmune diseases (IgG4-AID) are rare but collectively correspond to a significant group of devastating diseases affectingmany different organs, e.g. skin, brain, nerves and kidney in patients that often remain unresponsive to current treatments. IgG4-AIDhave commonalities indicating a shared underlying immunopathogenesis that make a joint approach to identify new therapeutictargets and test new treatment strategies feasible and necessary. We hypothesize that genetic risk factors and a dysregulatedimmune response may lead to an increased susceptibility to produce antibodies targeting self-proteins. These are of a specialsubclass called IgG4, which are usually harmless but can cause disease in these patients by interfering with normal functions in thebody. We are the first consortium that aims to study IgG4-AID comparatively, including pathogenic IgG4, and the cells, molecules andmechanisms involved in IgG4 autoantibody production, using an explorative multi-omics approaches in combination with state-ofthe-art cell and molecular biology methodology. We will establish a new humanized mouse model of IgG4-AID for the developmentand testing of a novel immune-apheresis based therapy aimed as immediate relief therapy for all IgG4-AID patients. Our innovativetraining program combines university-based and multidisciplinary research-based training with state-of the art web-based trainingand in-person trainings by the academic and non-academic sector. We aim to foster a new generation of experts in IgG4-AID that are1) are highly employable both in the academic and industry sectors and qualified for innovative multidisciplinary translationalresearch with a focus on biomedical product development and 2) equipped with the skillsets for digitalization, awareness for genderequality and diversity and competent in sustainable research and innovation approaches to address current and future challenges,such as climate change, social inequalities and pandemics.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз